Steris Plc (STE) - Q3 Fiscal 2025 Summary
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2024 (Q3 of Fiscal Year 2025). Steris Plc is a global provider of infection prevention products and services, operating through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Dental segment was divested in May 2024 and is reported as discontinued operations.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $1,370.6 million | $1,297.7 million | $3,979.0 million | $3,719.3 million |
| Gross Profit | $610.3 million | $560.0 million | $1,761.6 million | $1,635.3 million |
| Gross Margin | 44.5% | 43.2% | 44.3% | 44.0% |
| Operating Income | $245.3 million | $226.5 million | $650.5 million | $615.8 million |
| Net Income (Attributable to Shareholders) | $173.5 million | $140.7 million | $469.0 million | $379.6 million |
| Diluted EPS | $1.75 | $1.42 | $4.73 | $3.82 |
| Operating Cash Flow (YTD) | $887.3 million (vs. $718.5 million YTD 2023) | |||
| Free Cash Flow (YTD) | $588.1 million (vs. $457.0 million YTD 2023) | |||
| Total Debt | $2,163.7 million (Dec 31, 2024) vs. $3,206.1 million (Mar 31, 2024) | |||
| Cash & Equivalents | $155.2 million (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 5.6% in Q3 and 7.0% YTD, driven by higher volume and pricing in the Healthcare and AST segments. Service revenues grew 10.4% in Q3, while capital equipment revenues declined 8.2%.
- Profitability: Operating income rose 8.3% in Q3 and 5.6% YTD. Gross margins expanded due to favorable pricing and mix, partially offset by higher labor and overhead costs.
- Restructuring: The company incurred $2.2 million in restructuring expenses in Q3 and $30.7 million YTD related to a plan announced in May 2024, targeting approximately $25 million in annual operating income improvements.
- Debt Reduction: Total debt decreased significantly by approximately $1.04 billion since the start of the fiscal year, primarily due to the use of proceeds from the Dental segment divestiture to pay down term loans and credit facilities.
- Divestitures: The Dental segment was sold for $787.5 million (closed May 2024). The Controlled Environment Certification Services (CECS) business was sold for net proceeds of $41.9 million, generating a $19.3 million pre-tax gain.
Guidance, Outlook, and Risks
- Restructuring Outlook: Management expects the restructuring plan to be substantially complete by the end of Fiscal 2025, with benefits realized primarily in Fiscal 2026 and beyond. Additional costs of approximately $20 million are expected.
- Capital Allocation: The company repurchased $200 million of shares YTD and paid dividends of $1.66 per share. $300 million remains available under the share repurchase program.
- Legal Contingencies: Approximately 250 individual plaintiffs have filed suits in Illinois regarding ethylene oxide (EO) exposure. A mistrial occurred in January 2025; a retrial is scheduled for May 2025. No loss has been accrued as a range cannot be reasonably estimated.
- Tax Matters: The company is contesting IRS Notices of Deficiency regarding a deemed dividend inclusion from 2018, which could result in a cumulative tax liability of approximately $50 million if unsuccessful.
Investor Verification Checklist
- Dental Divestiture Proceeds: Verify the final cash consideration received and the specific allocation of funds used to reduce debt.
- Restructuring Execution: Monitor the timeline for the completion of the restructuring plan and the realization of the projected $25 million annual savings.
- EO Litigation Status: Track the outcome of the May 2025 retrial in Illinois regarding ethylene oxide exposure claims.
- Capital Equipment Backlog: Review the Healthcare segment backlog ($434.9 million) and Life Sciences backlog ($85.1 million) for trends in future revenue visibility.
- IRS Tax Dispute: Follow developments regarding the $50 million potential tax liability from the 2018 deemed dividend inclusion.